权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of Photoacoustic and Ultrasound Transrectal Probe for Prostate Biopsy

用于前列腺活检的光声和超声经直肠探头的开发

基本信息

批准号：
8811808
负责人：
NAVALGUND A RAO
金额：
$ 43.63万
依托单位：
ROCHESTER INSTITUTE OF TECHNOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-02-01 至 2019-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8811808
关键词：
Acoustics Anxiety Automobile Driving Benign Biopsy Cancerous Collaborations Computer-Aided Design Cues Detection Development Diagnosis Digital Rectal Examination Film Frequencies Gland Goals Health Human Image Image Guided Biopsy Imaging Device Indolent Institutes Lesion Light Lipids Lobe Localized Malignant Neoplasm Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of prostate Medical center Methods Modality Nature Needle biopsy procedure Nodule Noise Normal tissue morphology Optics Oxyhemoglobin Patient Monitoring Patients Performance Physicians Physiologic pulse Population Positioning Attribute Process Prostate Prostate-Specific Antigen Prostatic Neoplasms Quality of life Recurrence Relative (related person)Sampling Sensitivity and Specificity Side Signal Transduction Source System Technology Testing Thyroid Gland Time Tissues Translating Transrectal Ultrasound Ultrasonic wave Ultrasonography Universities Urethra Water absorption base capsule data acquisition deoxyhemoglobin design digital drug testing imaging modality imaging probe improved in vivo innovation lens new technology novel outcome forecast photoacoustic imaging polyvinylidene fluoride prostate biopsy public health relevance rectal research study response simulation software sound tool tumor

项目摘要

DESCRIPTION (provided by applicant): Indications of prostate cancer are predominantly an elevated prostate specific antigen (PSA) test or abnormal digital rectal exam (DRE), and prompt transrectal ultrasound (TRUS) guided biopsy of the prostate for definitive diagnosis. Often, there are cancers that are not visible (iso- echoic) on TRUS. Furthermore, in PSA screened populations, the accuracy of TRUS is only 52% due to false-positive results and is not reliable for the detection and localization of prostate cancer which is currently the only choice to perform biopsies. The aim is to exclude prostate cancer in patients with false positive PSA results and localize the cancer for targeted biopsies. To differentiate cancerous from benign prostate tissue, we propose to develop a handheld transrectal imaging probe based on multispectral photoacoustic (PA) imaging that can detect changes in relative concentrations of deoxyhemoglobin (dHb), oxyhemoglobin (HbO2), lipid and water in vivo. Specific Aims of our project include: Aim 1: To develop a dual modality system that will incorporate ultrasound (US) imaging into our existing ex-vivo PA imaging probe to generate co-registered dual modality images. Aim 2: To design and fabricate an in-vivo transrectal dual mode (US + PA) imaging probe capable of generating co-registered images suitable for prostate biopsy. Aim 3: Perform PA and US imaging experiments on the tissue equivalent phantoms to validate the performance and determine the quality metrics of the in-vivo dual mode imaging probe. The ultimate goal of this project is to develop an imaging modality that can clearly differentiate cancerous from benign prostate tissue in patients with positive PSA results. This will also help identify and monitor patients who need no further treatment, as well as aid in reducing false negative results due to poor cancer targeting of TRUS biopsy needles. This probe may help to reduce the TRUS biopsy rate or eliminate it altogether (if aggressive versus indolent cancers can be identified by multispectral photoacoustic imaging). Due to the functional nature of PA imaging, it is possible that the proposed probe may be a useful tool to evaluate prostate tumor prognosis, response to drugs, and detection of tumor recurrence.

描述（由申请方提供）：前列腺癌的适应症主要是前列腺特异性抗原（PSA）检测升高或直肠指检（DRE）异常，以及及时经直肠超声（TRUS）引导前列腺活检以进行明确诊断。通常，有一些癌症在TRUS上不可见（等回声）。此外，在PSA筛查人群中，由于假阳性结果，TRUS的准确性仅为52%，并且对于目前唯一的选择进行的前列腺癌的检测和定位不可靠活组织检查目的是排除PSA结果假阳性的患者中的前列腺癌，并定位癌症进行靶向活检。为了区分良性前列腺癌组织，我们建议开发一种基于多光谱光声（PA）成像的手持式经直肠成像探头，该探头可以检测体内脱氧血红蛋白（dHb）、氧合血红蛋白（HbO2）、脂质和水的相对浓度变化。我们项目的具体目标包括：目标1：开发一种双模态系统，将超声（US）成像纳入我们现有的体外PA成像探头，以生成共配准的双模态图像。目标二：设计和制造一种体内经直肠双模式（US + PA）成像探头，能够生成适用于前列腺活检的共配准图像。目标三：在组织等效体模上进行PA和US成像实验，以确认性能并确定体内双模成像探头的质量指标。该项目的最终目标是开发一种成像模式，可以清楚地区分PSA阳性患者的癌性前列腺组织和良性前列腺组织。这也将有助于识别和监测不需要进一步治疗的患者，并有助于减少由于TRUS活检针的癌症靶向性差而导致的假阴性结果。这种探头可能有助于降低TRUS活检率或完全消除TRUS活检率（如果可以通过多光谱光声成像识别侵袭性与惰性癌症）。由于PA成像的功能性质，所提出的探针可能是评估前列腺肿瘤预后、对药物的反应和检测肿瘤复发的有用工具。